VivoSeq
Other

Lenalidomide

0

Pipeline Programs↗

16

Active Trials↗

5

Companies Involved↗

Lenalidomide is an early-stage landscape with 0 programs across 5 companies. The most active players are Bristol-Myers Squibb, Amgen, Oncotherapeutics.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

64/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalO

Oncotherapeutics

0 programs

PreclinicalI

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

0 programs

PreclinicalIncyte logo

Incyte

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

75

clinical trials

Completed30 · 40%
Terminated12 · 16%
Unknown status12 · 16%
Recruiting10 · 13%
Active, not recruiting6 · 8%
Withdrawn4 · 5%
Other1 · 1%

Clinical Trials

Trial Activity

75 trials

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06792825·65 enrolled
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
Recruiting·NNOBO Medicine·Phase 2·NCT06737250·33 enrolled
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05615636·36 enrolled
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Recruiting·UUniversity of Cologne·Phase 2·NCT05583071·20 enrolled
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT07072221·40 enrolled
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06760156·28 enrolled
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Recruiting·IIntergroupe Francophone du Myelome·Phase 3·NCT06918002·824 enrolled
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07448324·50 enrolled
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
Recruiting·PPETHEMA Foundation·Phase 1/2·NCT05060627·60 enrolled
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04432714·81 enrolled
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT02886065·19 enrolled
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Active, not recruiting·SWOG Cancer Research Network·Phase 3·NCT04071457·1,100 enrolled
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT03863184·37 enrolled
Lenalidomide for Adult Histiocyte Disorders
Active, not recruiting·—·Phase 2·NCT02523040·12 enrolled
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
Active, not recruiting·IInstitut Curie·Phase 1/2·NCT04446962·118 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)